De-escalation of Disease-Modifying Therapy for People with Multiple Sclerosis Due to Safety Considerations: Characterizing 1-Year Outcomes in 25 People Who Switched from Ocrelizumab to Diroximel Fumarate.
Mark GudesblattBarbara BumsteadMarijean BuhseMyassar ZarifSarah A MorrowJacqueline A NicholasLaura M HancockJeffrey WilkenJoanna WellerNicole ScottAnne GockeJames B LewinOlivia KaczmarekJason P MendozaDaniel GolanPublished in: Advances in therapy (2024)
These preliminary findings suggest that transition to DRF from OCRE may be an effective treatment option for people with RRMS who are clinically stable but may need to switch for reasons unrelated to effectiveness. Longer follow-up times on larger samples are needed to confirm these observations.